Studies of walking ability in peripheral artery disease answer a different question from whether a GLP-1 drug can repair nerves affected by diabetes. The largest neuropathy study discussed here tracked foot complications in health records. Smaller studies evaluated nerve function and pain directly.
What the foot complication study found
Researchers matched 19,770 adults with type 2 diabetes and neuropathy starting a GLP-1 receptor agonist to 19,770 starting a DPP-4 inhibitor. At one year, a foot ulcer had been recorded for 2.2% versus 2.7%, a difference of about five per 1,000 people (hazard ratio 0.813, 95% CI 0.716 to 0.922) [1].
Charcot neuroarthropathy, which damages bones and joints in a foot with reduced sensation, was recorded in 0.3% versus 0.2%, a difference of roughly one per 1,000 based on the rounded rates. The hazard ratio was 1.993 (95% CI 1.297 to 3.064). Amputation and bone infection rates were similar in both groups. This observational study did not measure nerve function or show whether the drugs caused the differences.
Do GLP-1 drugs improve nerve function?
In a small, open-label randomized trial of 46 adults with type 2 diabetes and mild to moderate neuropathy, 18 months of exenatide showed no statistically significant advantage over insulin glargine on measured neuropathy outcomes, including nerve conduction and nerve fiber density[2].
A 2026 cross-sectional study evaluated 500 adults with type 2 diabetes. It found painful neuropathy in 10.1% of people already taking a GLP-1 drug versus 35.1% of those on standard treatment and 28.3% of those taking an SGLT2 inhibitor [3]. Because the researchers assessed the groups at one point in time, they could not tell whether the medication came before the difference in symptoms or whether treatment improved anyone’s nerve function.